These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31693661)

  • 1. "Cheaper and better": Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia.
    Eid Rodríguez D; San Sebastian M; Pulkki-Brännström AM
    PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007788. PubMed ID: 31693661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
    Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economic evaluation of moist wound care in chronic cutaneous leishmaniasis ulcers in Afghanistan.
    Stahl HC; Ahmadi F; Nahzat SM; Dong HJ; Stahl KW; Sauerborn R
    Infect Dis Poverty; 2018 Feb; 7(1):12. PubMed ID: 29444705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis.
    Cardona-Arias JA; López-Carvajal L; Tamayo Plata MP; Vélez ID
    J Evid Based Med; 2017 May; 10(2):81-90. PubMed ID: 28276641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
    Bermúdez H; Rojas E; Garcia L; Desjeux P; Dujardin JC; Boelaert M; Chappuis F
    Ann Trop Med Parasitol; 2006 Oct; 100(7):591-600. PubMed ID: 16989685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
    Brito NC; Rabello A; Cota GF
    PLoS One; 2017; 12(9):e0184777. PubMed ID: 28926630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis.
    Yesilova Y; Surucu HA; Ardic N; Aksoy M; Yesilova A; Oghumu S; Satoskar AR
    J Dermatolog Treat; 2016; 27(1):83-7. PubMed ID: 26105204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.
    Soto J; Valda-Rodriquez L; Toledo J; Vera-Navarro L; Luz M; Monasterios-Torrico H; Vega J; Berman J
    Am J Trop Med Hyg; 2004 Nov; 71(5):577-81. PubMed ID: 15569787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment of cutaneous leishmaniasis with amphotericin B; a case of unresponsive to pentavalent antimony therapy].
    Yeşilova Y; Turan E; Sürücü HA; Aksoy M; Özbilgin A
    Turkiye Parazitol Derg; 2015 Mar; 39(1):63-5. PubMed ID: 25917587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global distribution of treatment resistance gene markers for leishmaniasis.
    Salari S; Bamorovat M; Sharifi I; Almani PGN
    J Clin Lab Anal; 2022 Aug; 36(8):e24599. PubMed ID: 35808933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
    Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis.
    Tuon FF; Amato VS; Graf ME; Siqueira AM; Nicodemo AC; Amato Neto V
    Int J Dermatol; 2008 Feb; 47(2):109-24. PubMed ID: 18211479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
    Momeni AZ; Aminjavaheri M
    Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
    Brito NC; Machado de Assis TS; Rabello A; Cota G
    PLoS Negl Trop Dis; 2019 Dec; 13(12):e0007856. PubMed ID: 31805052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pentavalent antimonial compounds used in the treatment of cutaneous leishmaniasis on hemogram and biochemical parameters.
    An I; Harman M; Esen M; Çelik H
    Cutan Ocul Toxicol; 2019 Sep; 38(3):294-297. PubMed ID: 31039622
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R; Handjani F; Nouhpisheh MK
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application].
    Henao HH; Osorio Y; Saravia NG; Gómez A; Travi B
    Biomedica; 2004 Dec; 24(4):393-402. PubMed ID: 15678803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of cutaneous leishmaniasis.
    Hepburn NC
    Curr Opin Infect Dis; 2001 Apr; 14(2):151-4. PubMed ID: 11979125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.